ID   HOS
AC   CVCL_0312
DR   BTO; BTO:0003904
DR   CLO; CLO_0003795
DR   CLO; CLO_0050810
DR   EFO; EFO_0002196
DR   MCCL; MCC:0000205
DR   CLDB; cl1702
DR   CLDB; cl1706
DR   CLDB; cl7155
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-1543
DR   BCRC; 60308
DR   BCRJ; 0339
DR   BioSample; SAMN01821560
DR   BioSample; SAMN01821729
DR   BioSample; SAMN03471393
DR   BioSample; SAMN10987602
DR   cancercelllines; CVCL_0312
DR   CCRID; 1101HUM-PUMC000038
DR   CCRID; 4201HUM-CCTCC00333
DR   CCRID; 5301HUM-KCB15015YJ
DR   CCTCC; GDC0251
DR   CCTCC; GDC0333
DR   Cell_Model_Passport; SIDM00806
DR   ChEMBL-Cells; CHEMBL3308811
DR   ChEMBL-Targets; CHEMBL614173
DR   ChEMBL-Targets; CHEMBL614736
DR   CLS; 300449
DR   CLS; 300468
DR   Cosmic; 687928
DR   Cosmic; 759899
DR   Cosmic; 907060
DR   Cosmic; 931037
DR   Cosmic; 931910
DR   Cosmic; 1044082
DR   Cosmic; 1070840
DR   Cosmic; 1074391
DR   Cosmic; 1176621
DR   Cosmic; 1529902
DR   Cosmic; 2816208
DR   Cosmic-CLP; 907060
DR   DepMap; ACH-000613
DR   ECACC; 87070202
DR   EGA; EGAS00001000978
DR   GDSC; 907060
DR   GEO; GSM170248
DR   GEO; GSM185087
DR   GEO; GSM185088
DR   GEO; GSM320827
DR   GEO; GSM827319
DR   GEO; GSM879208
DR   GEO; GSM887088
DR   GEO; GSM888159
DR   GEO; GSM1669891
DR   GEO; GSM1676300
DR   GEO; GSM1701635
DR   GEO; GSM1914984
DR   GEO; GSM1914985
DR   GEO; GSM1914986
DR   GEO; GSM1914987
DR   GEO; GSM1915023
DR   GEO; GSM1915024
DR   GEO; GSM2635315
DR   GEO; GSM2635316
DR   GEO; GSM5087472
DR   GEO; GSM5087473
DR   GEO; GSM5087474
DR   GEO; GSM5087475
DR   GEO; GSM5087476
DR   GEO; GSM5087477
DR   IARC_TP53; 27020
DR   ICLC; HTL04003
DR   IGRhCellID; HOS
DR   IZSLER; BS TCL 69
DR   JCRB; IFO50106
DR   KCB; KCB 2015015YJ
DR   LiGeA; CCLE_703
DR   LINCS_LDP; LCL-1421
DR   PharmacoDB; HOS_563_2019
DR   PRIDE; PXD022868
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0312
DR   PubChem_Cell_line; CVCL_0312
DR   RCB; RCB0992
DR   Wikidata; Q54890160
RX   PubMed=1385192;
RX   PubMed=2233717;
RX   PubMed=2463881;
RX   PubMed=2823272;
RX   PubMed=6954533;
RX   PubMed=12645653;
RX   PubMed=15150091;
RX   PubMed=15289353;
RX   PubMed=17981215;
RX   PubMed=19787792;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=21519327;
RX   PubMed=22460905;
RX   PubMed=23144859;
RX   PubMed=26320182;
RX   PubMed=26351324;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=35839778;
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/h/cell-lines-detail-420.html
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   Doubling time: ~36 hours (PubMed=21519327).
CC   HLA typing: A*02:11; B*52:01; C*12:02 (PubMed=15289353).
CC   HLA typing: A*02:11,02:11; B*52:01,52:01; C*12:02,12:02; DQA1*02:01,02:01; DRB1*15:02,13:60 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19787792).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (PubMed=19787792; Cosmic-CLP; DepMap).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: H3K4me1 ChIP-seq epigenome analysis.
CC   Omics: H3K27ac ChIP-seq epigenome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=1.17%; East Asian, South=3.52%; South Asian=35.51%; European, North=0%; European, South=59.79% (PubMed=30894373).
CC   Discontinued: CLS; 300468; true.
CC   Derived from site: In situ; Bone, right femur; UBERON=UBERON_0000981.
ST   Source(s): ATCC; CCRID; CLS; Cosmic-CLP; ECACC; JCRB; PubMed=19787792; RCB
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D12S391: 20
ST   D13S317: 12
ST   D16S539: 10,13
ST   D18S51: 14
ST   D19S433: 13
ST   D21S11: 31.2,32.2
ST   D2S1338: 24,25
ST   D2S441: 10
ST   D3S1358: 15
ST   D5S818: 13
ST   D6S1043: 18
ST   D7S820: 11,12
ST   D8S1179: 14
ST   FGA: 24
ST   Penta D: 9,10
ST   Penta E: 7,12
ST   SE33: 21
ST   TH01: 6
ST   TPOX: 8,11
ST   vWA: 18
DI   NCIt; C9145; Osteosarcoma
DI   ORDO; Orphanet_668; Osteosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   13Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 42
//
RX   PubMed=1385192; DOI=10.1016/0531-5565(92)90007-m;
RA   Fleming T.P., Matsui T., Aaronson S.A.;
RT   "Platelet-derived growth factor (PDGF) receptor activation in cell
RT   transformation and human malignancy.";
RL   Exp. Gerontol. 27:523-532(1992).
//
RX   PubMed=2233717; DOI=10.1128/mcb.10.11.5772-5781.1990;
RA   Diller L., Kassel J., Nelson C.E., Gryka M.A., Litwak G., Gebhardt M.,
RA   Bressac B., Ozturk M., Baker S.J., Vogelstein B., Friend S.H.;
RT   "p53 functions as a cell cycle control protein in osteosarcomas.";
RL   Mol. Cell. Biol. 10:5772-5781(1990).
//
RX   PubMed=2463881; DOI=10.1093/carcin/10.2.265;
RA   Babich M.A., Day R.S. III;
RT   "Synergistic killing of virus-transformed human cells with interferon
RT   and N-methyl-N'-nitro-N-nitrosoguanidine.";
RL   Carcinogenesis 10:265-268(1989).
//
RX   PubMed=2823272; DOI=10.1073/pnas.84.21.7716;
RA   Masuda H., Miller C., Koeffler H.P., Battifora H.A., Cline M.J.;
RT   "Rearrangement of the p53 gene in human osteogenic sarcomas.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:7716-7719(1987).
//
RX   PubMed=6954533; DOI=10.1073/pnas.79.7.2194;
RA   Westin E.H., Gallo R.C., Arya S.K., Eva A., Souza L.M., Baluda M.A.,
RA   Aaronson S.A., Wong-Staal F.;
RT   "Differential expression of the amv gene in human hematopoietic
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 79:2194-2198(1982).
//
RX   PubMed=12645653; DOI=10.1016/S0165-4608(02)00685-4;
RA   Ozaki T., Neumann T., Wai D.H., Schaefer K.-L., van Valen F., Lindner N.,
RA   Scheel C., Boecker W., Winkelmann W., Dockhorn-Dworniczak B., Horst J.,
RA   Poremba C.;
RT   "Chromosomal alterations in osteosarcoma cell lines revealed by
RT   comparative genomic hybridization and multicolor karyotyping.";
RL   Cancer Genet. Cytogenet. 140:145-152(2003).
//
RX   PubMed=15150091; DOI=10.1158/0008-5472.CAN-03-0809;
RA   Schaefer K.-L., Brachwitz K., Wai D.H., Braun Y., Diallo R.,
RA   Korsching E., Eisenacher M., Voss R., van Valen F., Baer C., Selle B.,
RA   Spahn L., Liao S.-K., Lee K.A.W., Hogendoorn P.C.W., Reifenberger G.,
RA   Gabbert H.E., Poremba C.;
RT   "Expression profiling of t(12;22) positive clear cell sarcoma of soft
RT   tissue cell lines reveals characteristic up-regulation of potential
RT   new marker genes including ERBB3.";
RL   Cancer Res. 64:3395-3405(2004).
//
RX   PubMed=15289353; DOI=10.1158/0008-5472.CAN-04-0522;
RA   Tsukahara T., Nabeta Y., Kawaguchi S., Ikeda H., Sato Y.,
RA   Shimozawa K., Ida K., Asanuma H., Hirohashi Y., Torigoe T., Hiraga H.,
RA   Nagoya S., Wada T., Yamashita T., Sato N.;
RT   "Identification of human autologous cytotoxic T-lymphocyte-defined
RT   osteosarcoma gene that encodes a transcriptional regulator,
RT   papillomavirus binding factor.";
RL   Cancer Res. 64:5442-5448(2004).
//
RX   PubMed=17981215; DOI=10.1016/j.cancergencyto.2007.08.003;
RA   Selvarajah S., Yoshimoto M., Maire G., Paderova J., Bayani J.,
RA   Squire J.A., Zielenska M.;
RT   "Identification of cryptic microaberrations in osteosarcoma by
RT   high-definition oligonucleotide array comparative genomic
RT   hybridization.";
RL   Cancer Genet. Cytogenet. 179:52-61(2007).
//
RX   PubMed=19787792; DOI=10.1002/gcc.20717;
RA   Ottaviano L., Schaefer K.-L., Gajewski M., Huckenbeck W., Baldus S.E.,
RA   Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H.,
RA   Meza-Zepeda L.A., Serra M., Cleton-Jansen A.-M., Hogendoorn P.C.W.,
RA   Buerger H., Aigner T., Gabbert H.E., Poremba C.;
RT   "Molecular characterization of commonly used cell lines for bone tumor
RT   research: a trans-European EuroBoNet effort.";
RL   Genes Chromosomes Cancer 49:40-51(2010).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=21519327; DOI=10.1038/labinvest.2011.72;
RA   Mohseny A.B., Machado I., Cai Y.-P., Schaefer K.-L., Serra M.,
RA   Hogendoorn P.C.W., Llombart-Bosch A., Cleton-Jansen A.-M.;
RT   "Functional characterization of osteosarcoma cell lines provides
RT   representative models to study the human disease.";
RL   Lab. Invest. 91:1195-1205(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23144859; DOI=10.1371/journal.pone.0048262;
RA   Kresse S.H., Rydbeck H., Skarn M., Namlos H.M., Barragan-Polania A.H.,
RA   Cleton-Jansen A.-M., Serra M., Liestol K., Hogendoorn P.C.W., Hovig E.,
RA   Myklebost O., Meza-Zepeda L.A.;
RT   "Integrative analysis reveals relationships of genetic and epigenetic
RT   alterations in osteosarcoma.";
RL   PLoS ONE 7:E48262-E48262(2012).
//
RX   PubMed=26320182; DOI=10.18632/oncotarget.5177;
RA   Ren L., Mendoza A., Zhu J., Briggs J.W., Halsey C., Hong E.S.,
RA   Burkett S.S., Morrow J.J., Lizardo M.M., Osborne T., Li S.Q.,
RA   Luu H.H., Meltzer P.S., Khanna C.;
RT   "Characterization of the metastatic phenotype of a panel of
RT   established osteosarcoma cells.";
RL   Oncotarget 6:29469-29481(2015).
//
RX   PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074;
RA   Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E.,
RA   Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J.,
RA   Harris E., Monks A., Morris J.;
RT   "Sarcoma cell line screen of oncology drugs and investigational agents
RT   identifies patterns associated with gene and microRNA expression.";
RL   Mol. Cancer Ther. 14:2452-2462(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//